NGS Oncology Global Market Report 2025

Description

Next-generation sequencing (NGS) oncology involves the use of advanced sequencing technologies to examine the genetic composition of cancer cells. It helps identify specific mutations, genetic alterations, and biomarkers that can guide personalized treatment plans, predict responses to therapies, and enhance overall cancer management. NGS oncology facilitates precision medicine, where treatments are tailored to the genetic profile of the tumor.

The primary sequencing technologies in NGS oncology include targeted sequencing, genomics, transcriptomics, and epigenomics. Targeted sequencing is a genomic method that focuses on sequencing specific genes or regions within the genome to detect genetic variations linked to diseases or traits. These technologies are available in platforms, kits, and services. The workflow includes stages such as pre-sequencing, sequencing, and data analysis. They are applied in various areas, including genetic screening, hereditary genetic testing, hematological malignancies, solid tumors, and more. Key end users include hospitals and clinics, clinical research organizations (CROs), academic and research institutions, pharmaceutical and biotechnology companies, and others.

The NGS oncology market research report is one of a series of new reports from The Business Research Company that provides NGS oncology market statistics, including the NGS oncology industry global market size, regional shares, competitors with the NGS oncology market share, detailed NGS oncology market segments, market trends, and opportunities, and any further data you may need to thrive in the NGS oncology industry. This NGS oncology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The NGS oncology market size has grown rapidly in recent years. It will grow from $17.36 billion in 2024 to $19.39 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth during the historic period can be attributed to the increasing incidence of cancer, expanding research in cancer genomics, rising public awareness, development of healthcare infrastructure, and growing demand for personalized medicine.

The NGS oncology market size is expected to see rapid growth in the next few years. It will grow to $29.86 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The projected growth in the forecast period is driven by the expansion of companion diagnostics, rising cancer prevalence, increased government and healthcare investments, broader clinical applications, and growing interest in targeted therapies. Key trends expected in this period include the integration of AI and machine learning, progress in single-cell sequencing, improvements in sequencing platforms, advancements in liquid biopsy technology, and developments in high-throughput sequencing platforms.

The increasing prevalence of cancer is expected to drive the growth of the NGS oncology market in the coming years. Cancer is a condition where abnormal cells grow uncontrollably and spread to other parts of the body, disrupting normal bodily functions. The rising prevalence of cancer is primarily due to aging populations, as the risk of developing cancer increases with age. NGS oncology helps address this growing cancer burden by enabling early detection, accurate diagnosis, and personalized treatment through detailed genetic profiling of tumors. According to the American Cancer Society, a U.S.-based nonprofit organization, in 2022, around 20 million new cancer cases were reported globally, resulting in 9.7 million deaths. Driven mainly by population growth, the global cancer burden is expected to rise to 35 million cases by 2050. Thus, the increasing prevalence of cancer will significantly drive the expansion of the NGS oncology market.

Companies operating in the NGS oncology market are focusing on developing innovative solutions, such as liquid biopsy research assays, to enable non-invasive, real-time cancer detection and monitoring through the analysis of circulating tumor DNA. A liquid biopsy research assay is a diagnostic test that analyzes biological fluids such as blood to detect genetic mutations or molecular markers linked to cancer, allowing for non-invasive detection and monitoring. For example, in August 2024, Illumina Inc., a U.S.-based biotechnology company specializing in NGS technology, expanded its oncology portfolio for NovaSeq X Series users. The company introduced the newly validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assays. These advanced assays enable laboratories to expand their oncology research capabilities for both tissue and liquid biopsy samples, offering improved sequencing efficiency, reduced run times, and the ability to process larger sample volumes on the NovaSeq X Series for the first time.

In December 2024, Deerfield Management Company, a U.S.-based investment firm, acquired Singular Genomics for an undisclosed amount. This acquisition aims to strengthen Deerfield's portfolio by integrating Singular Genomics' next-generation sequencing and spatial multiomics technologies, advancing research and clinical applications. Singular Genomics is a U.S.-based biotechnology company specializing in NGS and multiomics technologies.

Major players in the NGS oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, and SciGenom Labs Pvt. Ltd.

North America was the largest region in the NGS oncology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in NGS oncology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the NGS oncology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The NGS oncology market consists of revenues earned by entities by providing services such as companion diagnostics, liquid biopsy analysis, genetic mutation analysis, bioinformatics, and data interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. The NGS oncology market also includes sales of target enrichment kits, library preparation kits, data analysis pipelines, bioinformatics software, and tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

NGS Oncology Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ngs oncology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ngs oncology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ngs oncology market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Sequencing Technology: Targeted Sequencing; Genomics; Transcriptomics; Epigenomics
2) By Offering: Platform; Kits; Services
3) By Workflow: Pre-Sequencing; Sequencing; Data Analysis
4) By Application: Genetic Screening; Hereditary Genetic Testing; Hematological Malignancies; Solid Tumors; Other Applications
5) By End User: Hospitals And Clinics; Clinical Research Organizations (CROs); Academic And Research Institutes; Pharmaceutical And Biotechnology Companies; Other End Users
Subsegments:
1) By Targeted Sequencing: Whole Exome Sequencing (WES); Amplicon-Based Sequencing; Hybridization-Based Sequencing
2) By Genomics: Whole Genome Sequencing (WGS); Structural Variant Detection; Copy Number Variation (CNV) Analysis
3) By Transcriptomics: RNA Sequencing; Single-Cell Transcriptomics; Non-coding RNA Analysis
4) By Epigenomics: DNA Methylation Sequencing; Chromatin Immunoprecipitation Sequencing; Histone Modification Analysis
Companies Mentioned: Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Eurofins Scientific SE; Illumina Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r35528

1. Executive Summary

2. NGS Oncology Market Characteristics

3. NGS Oncology Market Trends And Strategies

4. NGS Oncology Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global NGS Oncology Growth Analysis And Strategic Analysis Framework

5.1. Global NGS Oncology PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global NGS Oncology Market Growth Rate Analysis
5.4. Global NGS Oncology Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global NGS Oncology Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global NGS Oncology Total Addressable Market (TAM)

6. NGS Oncology Market Segmentation

6.1. Global NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Sequencing
Genomics
Transcriptomics
Epigenomics
6.2. Global NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Platform
Kits
Services
6.3. Global NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pre-Sequencing
Sequencing
Data Analysis
6.4. Global NGS Oncology Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Genetic Screening
Hereditary Genetic Testing
Hematological Malignancies
Solid Tumors
Other Applications
6.5. Global NGS Oncology Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Clinical Research Organizations (CROs)
Academic And Research Institutes
Pharmaceutical And Biotechnology Companies
Other End Users
6.6. Global NGS Oncology Market, Sub-Segmentation Of Targeted Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Whole Exome Sequencing (WES)
Amplicon-Based Sequencing
Hybridization-Based Sequencing
6.7. Global NGS Oncology Market, Sub-Segmentation Of Genomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Whole Genome Sequencing (WGS)
Structural Variant Detection
Copy Number Variation (CNV) Analysis
6.8. Global NGS Oncology Market, Sub-Segmentation Of Transcriptomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
RNA Sequencing
Single-Cell Transcriptomics
Non-coding RNA Analysis
6.9. Global NGS Oncology Market, Sub-Segmentation Of Epigenomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
DNA Methylation Sequencing
Chromatin Immunoprecipitation Sequencing
Histone Modification Analysis

7. NGS Oncology Market Regional And Country Analysis

7.1. Global NGS Oncology Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global NGS Oncology Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific NGS Oncology Market

8.1. Asia-Pacific NGS Oncology Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China NGS Oncology Market

9.1. China NGS Oncology Market Overview
9.2. China NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India NGS Oncology Market

10.1. India NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan NGS Oncology Market

11.1. Japan NGS Oncology Market Overview
11.2. Japan NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia NGS Oncology Market

12.1. Australia NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia NGS Oncology Market

13.1. Indonesia NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea NGS Oncology Market

14.1. South Korea NGS Oncology Market Overview
14.2. South Korea NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe NGS Oncology Market

15.1. Western Europe NGS Oncology Market Overview
15.2. Western Europe NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK NGS Oncology Market

16.1. UK NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany NGS Oncology Market

17.1. Germany NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France NGS Oncology Market

18.1. France NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy NGS Oncology Market

19.1. Italy NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain NGS Oncology Market

20.1. Spain NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe NGS Oncology Market

21.1. Eastern Europe NGS Oncology Market Overview
21.2. Eastern Europe NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia NGS Oncology Market

22.1. Russia NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America NGS Oncology Market

23.1. North America NGS Oncology Market Overview
23.2. North America NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA NGS Oncology Market

24.1. USA NGS Oncology Market Overview
24.2. USA NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada NGS Oncology Market

25.1. Canada NGS Oncology Market Overview
25.2. Canada NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America NGS Oncology Market

26.1. South America NGS Oncology Market Overview
26.2. South America NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil NGS Oncology Market

27.1. Brazil NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East NGS Oncology Market

28.1. Middle East NGS Oncology Market Overview
28.2. Middle East NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa NGS Oncology Market

29.1. Africa NGS Oncology Market Overview
29.2. Africa NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. NGS Oncology Market Competitive Landscape And Company Profiles

30.1. NGS Oncology Market Competitive Landscape
30.2. NGS Oncology Market Company Profiles
- 30.2.1. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

31. NGS Oncology Market Other Major And Innovative Companies

31.1. Qiagen N.V.
31.2. Tecan Trading AG
31.3. Myriad Genetics
31.4. Takara Bio Inc.
31.5. Beijing Genomics Institute (BGI)
31.6. Caris Life Sciences
31.7. Foundation Medicine
31.8. Paradigm Diagnostics
31.9. Pacific Bioscience
31.10. Horizon Discovery Group plc
31.11. Creative-Biolabs
31.12. Xcelris Labs Ltd.
31.13. Partek Inc.
31.14. 4baseCare
31.15. SciGenom Labs Pvt. Ltd.

32. Global NGS Oncology Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The NGS Oncology Market

34. Recent Developments In The NGS Oncology Market

35. NGS Oncology Market High Potential Countries, Segments and Strategies

35.1 NGS Oncology Market In 2029 - Countries Offering Most New Opportunities
35.2 NGS Oncology Market In 2029 - Segments Offering Most New Opportunities
35.3 NGS Oncology Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer